Adjuvant Chemotherapy for Colon Cancer

Surgery remains the only curative therapy for colon cancer. However, several studies during the last years have proved that systemic chemotherapy in the adjuvant setting definitely improves the curative rate for those patients with localized colon cancer. The combination of 5-fluorouracil (5-FU) and...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 26; no. 6C; pp. 4809 - 4815
Main Authors PALLIS, A. G, MOUZAS, I. A
Format Journal Article
LanguageEnglish
Published Attiki International Institute of Anticancer Research 01.11.2006
Subjects
Biological and medical sciences
Chemotherapy, Adjuvant
Colonic Neoplasms - drug therapy
Colonic Neoplasms - surgery
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Medical sciences
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Antineoplastic agent
leukovorin
Enzyme
DNA topoisomerase
Adjuvant treatment
Enzyme inhibitor
Malignant tumor
Colonic disease
Irinotecan
Alkylating agent
Chemotherapy
Isomerases
Colon cancer
Cancerology
Oxaliplatin
review
Digestive diseases
Intestinal disease
Adjuvant
Bibliographic review
Platinum II Complexes
5-FU
Online AccessGet full text

Cover

More Information
Summary:Surgery remains the only curative therapy for colon cancer. However, several studies during the last years have proved that systemic chemotherapy in the adjuvant setting definitely improves the curative rate for those patients with localized colon cancer. The combination of 5-fluorouracil (5-FU) and leukovorin (LV) remained the reference treatment for over a decade. However, oxaliplatin-based chemotherapy has emerged as the new standard of care in adjuvant treatment of stage III colon cancer. The role of adjuvant therapy in stage II cancers remains controversial and its routine use is recommended only in high risk patients. This review focuses on the efficacy, safety and toxicity of several drugs used in the adjuvant treatment of colon cancer and on clinical issues, such as the timing for initiation of chemotherapy, its duration and treatment of special patient subgroups, such as stage II or elderly patients.
ISSN:0250-7005
1791-7530